KRYSTAL BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 160 USD | -0.96% |
|
-1.71% | +29.01% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 958.5 | 1,182 | 1,742 | 2,040 | 3,499 | 4,571 | - | - |
| Enterprise Value (EV) 1 | 774.3 | 918.1 | 1,304 | 1,661 | 2,905 | 3,977 | 3,772 | 3,427 |
| P/E ratio | -46.2 x | -35.1 x | -22.3 x | -14.4 x | 318 x | 70.8 x | 29.1 x | 18.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 69 x | 17.2 x | 10.7 x | 7.49 x |
| EV / Revenue | - | - | - | - | 57.3 x | 14.9 x | 8.81 x | 5.62 x |
| EV / EBITDA | -36.3 x | -29.5 x | -19.9 x | -11.5 x | -27.4 x | 59 x | 23 x | 11.5 x |
| EV / FCF | - | -22.4 x | -11.2 x | -10.8 x | -28.9 x | 30.5 x | 15.7 x | 9.93 x |
| FCF Yield | - | -4.46% | -8.92% | -9.25% | -3.46% | 3.28% | 6.36% | 10.1% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,308 | 19,708 | 24,906 | 25,748 | 28,206 | 28,558 | - | - |
| Reference price 2 | 55.38 | 60.00 | 69.95 | 79.22 | 124.1 | 160.0 | 160.0 | 160.0 |
| Announcement Date | 3/10/20 | 3/1/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 50.7 | 266.4 | 427.9 | 610 |
| EBITDA 1 | -21.33 | -31.15 | -65.51 | -144.1 | -106 | 67.35 | 164.3 | 298.3 |
| EBIT 1 | -22.08 | -33 | -68.28 | -145.2 | -109.7 | 55.28 | 174 | 306.1 |
| Operating Margin | - | - | - | - | -216.43% | 20.75% | 40.65% | 50.19% |
| Earnings before Tax (EBT) 1 | -19.09 | -32.17 | -69.57 | -140 | 12.9 | 72.98 | 211 | 340.2 |
| Net income 1 | -19.09 | -32.17 | -69.57 | -140 | 10.93 | 62.79 | 159.8 | 264.5 |
| Net margin | - | - | - | - | 21.56% | 23.57% | 37.35% | 43.37% |
| EPS 2 | -1.200 | -1.710 | -3.130 | -5.490 | 0.3900 | 2.261 | 5.506 | 8.630 |
| Free Cash Flow 1 | - | -40.93 | -116.3 | -153.5 | -100.6 | 130.4 | 239.8 | 345.1 |
| FCF margin | - | - | - | - | -198.43% | 48.94% | 56.05% | 56.58% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 193.61% | 145.98% | 115.71% |
| FCF Conversion (Net income) | - | - | - | - | - | 207.68% | 150.06% | 130.46% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/20 | 3/1/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 8.556 | 42.14 | 45.25 | 64.71 | 75.42 | 82.44 | - | - |
| EBITDA 1 | -21.09 | - | - | - | - | - | - | - | 4.298 | 9.545 | 31.2 | 37.83 | 39.98 | - | - |
| EBIT 1 | -21.88 | -25.22 | -28.75 | -31.45 | -34.77 | -48.82 | -38.05 | -25.99 | 3.138 | 5.816 | 18.59 | 23.58 | 25.43 | - | - |
| Operating Margin | - | - | - | - | - | - | - | -303.8% | 7.45% | 12.85% | 28.72% | 31.26% | 30.85% | - | - |
| Earnings before Tax (EBT) 1 | -21.81 | -49.96 | -28.11 | -29.85 | -32.05 | -45.3 | -33.21 | 80.75 | 10.66 | 0.932 | 18.35 | 24.25 | 24.2 | - | - |
| Net income 1 | -21.81 | -49.96 | -28.11 | -29.85 | -32.05 | -45.3 | -33.21 | 80.75 | 8.692 | 0.932 | 16.62 | 21.55 | 21.78 | - | - |
| Net margin | - | - | - | - | - | - | - | 943.75% | 20.63% | 2.06% | 25.68% | 28.57% | 26.42% | - | - |
| EPS 2 | -0.9500 | -1.990 | -1.100 | -1.170 | -1.250 | -1.760 | -1.250 | 2.790 | 0.3100 | 0.0300 | 0.6214 | 0.7300 | 0.7500 | 1.410 | 1.270 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/8/22 | 11/7/22 | 2/27/23 | 5/8/23 | 8/7/23 | 11/6/23 | 2/26/24 | 5/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 184 | 264 | 438 | 379 | 594 | 594 | 799 | 1,144 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -40.9 | -116 | -154 | -101 | 130 | 240 | 345 |
| ROE (net income / shareholders' equity) | - | - | -15.7% | -25.1% | -11.4% | 12.8% | 18.7% | 17.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -2.160 | -3.950 | -3.200 | 2.940 | 4.020 | - |
| Capex 1 | - | 14.8 | 68.3 | 0.05 | 11.8 | 7.3 | 10 | - |
| Capex / Sales | - | - | - | - | 23.27% | 2.74% | 2.34% | - |
| Announcement Date | 3/10/20 | 3/1/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
160
USD
Average target price
189
USD
Spread / Average Target
+18.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.01% | 4.57B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- KRYS Stock
- Financials Krystal Biotech, Inc.
